Tech Company Financing Transactions
Eyevensys Funding Round
Eyevensys, based in Paris, secured $10.1 million from Pontifax Fund and private investors.
Transaction Overview
Company Name
Announced On
9/16/2016
Transaction Type
Venture Equity
Amount
$10,116,900
Round
Series A
Investors
Pontifax Fund (Lead Investor) (Ohad Hammer)
Proceeds Purpose
Eyevensys will use the funds raised to secure the clinical development of its lead product candidate EYS606 that will enter into an open-label Phase Ib study in premier Ophthalmological Centres in France and in the UK by the end of 2016 as a potential treatment for Non-Infectious Uveitis (NIU).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11 rue Watt -- Bat B
Paris, 75013
France
Paris, 75013
France
Phone
Website
Email Address
Overview
Eyevensys is dedicated to the research and development of innovative therapies for the treatment of ocular diseases by non viral gene therapy. Eyevensys S.A.S. is a privately held biotechnology company developing a game changing approach to express therapeutic proteins in situ for the treatment of major ophthalmic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patricia Zilliox
Chief Medical Officer
Ronald Buggage
Chief Scientific Officer
Francine Behar-Cohen
Browse more venture capital transactions:
Prev: 9/16/2016: Ellevest venture capital transaction
Next: 9/16/2016: Resilinc venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. All VC database entries on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs